An Inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model

American Journal of Respiratory Cell and Molecular Biology

Volumn 50, Issue 1, 2014, Pages 158-169

  Jarman, Elizabeth R ^a   Khambata, Valerie S ^a   Cope, Claire ^a   Jones, Peter ^a   Roger, Jan ^a   Ye, Li Yun ^a   Duggan, Nicholas ^a   Head, Denise ^a   Pearce, Andrew ^a   Press, Neil J ^a   Bellenie, Ben ^a   Sohal, Bindi ^a   Jarai, Gabor ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Fibroblasts; NADPH oxidase 4 (Nox4); Pulmonary fibrosis; Transforming growth factor

Indexed keywords

BLEOMYCIN; COLLAGEN; COLLAGEN 1ALPHA 1; COLLAGEN 3ALPHA 1; FIBRONECTIN; HYPOXIA INDUCIBLE FACTOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; LUNG PARENCHYMA; LUNG VASCULAR RESISTANCE; MALE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; RAT; RODENT DISEASE; RODENT MODEL; UPREGULATION;

ACTINS; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE III; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; FIBRONECTINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MUSCLE, SMOOTH; MYOFIBROBLASTS; NADPH OXIDASE; RATS; RATS, SPRAGUE-DAWLEY; RODENT DISEASES; SMALL MOLECULE LIBRARIES; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84891811928     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0174OC     Document Type: Article

References (49)

1. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339-1350.
2. Strieter RM. What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc 2008;5:305-310. (Pubitemid 351520676)
3. Nathan SD, Shlobin OA, Ahmad S, Urbane K, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007;131:657-663. (Pubitemid 46446854)
4. Fernandez IE, Eickelberg O. The impact of TGF-b on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 2012;9:111-116.
5. Kinnula VL, Myllärniemi M. Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis. Antioxid Redox Signal 2008;10:727-738. (Pubitemid 351225901)
6. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995;152:1055-1060.
7. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al.; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-2242. (Pubitemid 41697286)
8. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-1977.
9. Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87: 245-313. (Pubitemid 46209993)
10. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 2006;18:69-82. (Pubitemid 41415716)
11. Liu R-M, Choi J, Wu J-H, Gaston Pravia KA, Lewis KM, Brand JD, Mochel NS, Krzywanski DM, Lambeth JD, Hagood JS, et al. Oxidative modification of nuclear mitogen-activated protein kinase phosphatase 1 is involved in transforming growth factor b1-induced expression of plasminogen activator inhibitor 1 in fibroblasts. J Biol Chem 2010;285:16239-16247.
12. Martin-Garrido A, Brown DI, Lyle AN, Dikalova A, Seidel-Rogol B, Lasségue B, San Martín A, Griendling KK. NADPH oxidase 4 mediates TGF-b-induced smooth muscle a-actin via p38MAPK and serum response factor. Free Radic Biol Med 2011;50:354-362.
13. Koli K, Myllärniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-b activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 2008;10:333-342.
14. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-1081.
15. Pache J-C, Carnesecchi S, Deffert C, Donati Y, Herrmann FR, Barazzone-Argiroffo C, Krause KH. NOX-4 is expressed in thickened pulmonary arteries in idiopathic pulmonary fibrosis. Nat Med 2011; 17:31-32, author reply 32-33.
16. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65:733-738.
17. Frey RS, Ushio-Fukai M, Malik AB. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009;11:791-810.
18. Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, Preynat-Seauve O, Guichard C, Arbiser JL, Banfi B, Pache JC, et al. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal 2011;15:607-619.
19. Korfei M, Schmitt S, Ruppert C, Henneke I, Markart P, Loeh B, Mahavadi P, Wygrecka M, Klepetko W, Fink L, et al. Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. J Proteome Res 2011;10:2185-2205.
20. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53:7715-7730.
21. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005;313: 943-951. (Pubitemid 40726998)
22. Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, Kikkawa H, Asano S, Kinoshita M. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 2007;83:39-46. (Pubitemid 46842964)
23. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-470. (Pubitemid 18098428)
24. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53.
25. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Fórró L, Schlegel W, Krause KH. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 2007;406:105-114. (Pubitemid 47264740)
26. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 2011;50:408-416.
27. Galuppo M, Esposito E, Mazzon E, Di Paola R, Paterniti I, Impellizzeri D, Cuzzocrea S. MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn Schmiedebergs Arch Pharmacol 2011;384:21-37.
28. Hoyles RK, Derrett-Smith EC, Khan K, Shiwen X, Howat SL, Wells AU, Abraham DJ, Denton CP. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor b receptor. Am J Respir Crit Care Med 2011;183:249-261.
29. Li M, Krishnaveni MS, Li C, Zhou B, Xing Y, Banfalvi A, Li A, Lombardi V, Akbari O, Borok Z, et al. Epithelium-specific deletion of TGF-b receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J Clin Invest 2011;121:277-287.
30. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, Karwande SV, Stringham JC, Bull DA, Gleich M, et al. Transforming growth factor-b1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006;290: L661-L673. (Pubitemid 43725071)
31. Mittal M, Roth M, König P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, et al. Hypoxiadependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 2007;101:258-267. (Pubitemid 47344075)
32. Perrotta I, Sciangula A, Perrotta E, Donato G, Cassese M. Ultrastructural analysis and electron microscopic localization of Nox4 in healthy and atherosclerotic human aorta. Ultrastruct Pathol 2011;35:1-6.
33. Cutroneo KR, White SL, Phan SH, Ehrlich HP. Therapies for bleomycin induced lung fibrosis through regulation of transforming growth factor-beta 1 induced collagen gene expression. J Cell Physiol 2007; 21:585-598.
34. Chuang-Tsai S, Sisson TH, Hattori N, Tsai CG, Subbotina NM, Hanson KE, Simon RH. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 2003;163:445-452. (Pubitemid 36909408)
35. Senoo T, Hattori N, Tanimoto T, Furonaka M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Yokoyama A, Kohno N. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010;65:334-340.
36. Huang W-T, Vayalil PK, Miyata T, Hagood J, Liu R-M. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol 2012;46:87-95.
37. Vayalil PK, Iles KE, Choi J, Yi A-K, Postlethwait EM, Liu R-M. Glutathione suppresses TGF-b-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am J Physiol Lung Cell Mol Physiol 2007;293:L1281-L1292. (Pubitemid 350159412)
38. Zhang M, Brewer AC, Schröder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 2010; 107:18121-18126.
39. Diebold I, Petry A, Hess J, Görlach A. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell 2010;21:2087-2096.
40. Ismail S, Sturrock A, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T, Hoidal J. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-beta1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol 2009;296:L489-L499.
41. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010;8:1000479.
42. Gavazzi G, Deffert C, Trocme C, Schäppi M, Herrmann FR, Krause KH. NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 2007;50:189-196. (Pubitemid 46992019)
43. Lee MY, San Martin A, Mehta PK, Dikalova AE, Garrido AM, Datla SR, Lyons E, Krause KH, Banfi B, Lambeth JD, et al. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol 2009;29:480-487.
44. Lassegue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculture. Atherioscler Thromb Vasc Biol 2010; 30:653-661.
45. Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F. Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol 2007;27:2319-2324. (Pubitemid 350203945)
46. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 2011;31:1368-1376.
47. Green DE, Murphy TC, Kang B-Y, Kleinhenz JM, Szyndralewiez C, Page P, Sutliff RL, Hart CM. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol 2012;47:718-726.
48. Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schröder K, Brandes RP, Devaraj S, Török NJ. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 2012;53:289-296.
49. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CRJ, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 2013;124:191-202.